Full Text View
Tabular View
No Study Results Posted
Related Studies
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
This study is ongoing, but not recruiting participants.
Study NCT00839956   Information provided by Fred Hutchinson Cancer Research Center

First Received on February 7, 2009.   Last Updated on May 13, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Additional conditions recognized in this trial
Multiple Myeloma
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
bortezomib
vorinostat
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services